Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.
BACKGROUND
Paramyxoviral infections are reported in 6% to 21% of lung transplant recipients. Aerosolized ribavirin is used to treat paramyoxviral infections, but data on outcomes of this treatment in lung transplant patients are limited.


METHODS
Lung recipients treated with aerosolized ribavirin from 1992 through 2000 for pulmonary respiratory syncytial virus (RSV) or parainfluenza virus (PIV) infection were assessed for the following variables: age; gender; underlying diagnosis; time from transplantation; duration of illness; clinical symptoms; and change from baseline FEV(1) (forced expiratory volume in 1 second). Outcomes included FEV(1) values at 30 and 90 days, need for intubation, development of acute rejection or obliterative bronchiolitis (OB) in the year after treatment; and 90-day and overall mortality.


RESULTS
Fifteen patients received ribavirin for a median of 5 days (range 3 to 7) for 17 episodes of RSV (n = 12) or PIV (n = 5) infection. The clinical presentations of RSV and PIV infection were similar. Infection occurred a median of 520 days (range 7 to 1700) after transplantation. Three episodes required intubation; 2 episodes were fatal accounting for a 90-day mortality per episode of 12%. The FEV(1) at presentation declined by 25% (range 4% to 44%) from baseline. In 3 patients the FEV(1) did not return to baseline by 90 days or thereafter. All 3 patients had underlying pulmonary fibrosis (IPF) vs no IPF in 0 of 9 evaluable patients who recovered (p = 0.009). There was no correlation between response to ribavirin and subsequent development of OB.


CONCLUSIONS
About 33% of lung transplant patients with lower respiratory tract paramyxoviral infections who were treated with inhaled ribavirin died or did not return to baseline FEV(1). This effect was acute and not associated with later complications, including OB. Underlying IPF may be a risk factor for failure to return to baseline. Larger, prospective, multicenter studies are required to confirm these findings.
McCurdy
Lewis H
LH
Infectious Diseases, Vanderbilt Transplant Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37027, USA.
Milstone
Aaron
A
Dummer
Stephen
S
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018893:Bronchoalveolar Lavage; D003131:Combined Modality Therapy; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006084:Graft Rejection / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000503:physiopathology / Q000628:therapy / Q000821:virology; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D018184:Paramyxoviridae Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology*; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D015995:Prevalence; D012189:Retrospective Studies; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D012621:Seasons; D013714:Tennessee / Q000453:epidemiology; D016896:Treatment Outcome
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D012254:Ribavirin